Real-World check: does daily semaglutide pill tame blood sugar?

NCT ID NCT04537637

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study followed 99 adults with type 2 diabetes in Denmark who were already prescribed once-daily oral semaglutide (Rybelsus). Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months, along with patient questionnaires. The goal was to see how well the medication works outside of a controlled clinical setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this study could confirm that oral semaglutide helps control blood sugar and weight in real-world settings, supporting its use for type 2 diabetes management.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (99 participants) and limited to Denmark, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Show contact details

Locations

Master Centre for Denmark

Copenhagen S, 2300, Denmark
Novo Nordisk investigational site

Søborg, 2860, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.